Navigation Links
AMDL, Inc. Closes Private Placement of Convertible Notes
Date:9/16/2008

the shares issued will not be registered. The shares issuable on conversion carry "piggy-back" registration rights should the Company file a registration statement subsequent to conversion.

In the event of a forced conversion into common shares in the public offering, note holders will be subject to a lock-up on any remaining shares not sold in the offering for 90 days after the public offering. Upon any conversion of the notes into common stock of the Company, the Company shall also issue warrants to purchase common stock to the converting investors in the amount equal to 50% of the number of shares of common stock into which their notes were converted. Warrants shall have a term of five years from the date of issuance and shall be exercisable at a price equal to 120% of the closing price of the Company's common stock on the date of conversion; provided however, in no event shall the exercise price of the warrants be less than 120% of the five day volume average weighted price (VWAP) of the Company's common stock the on closing date of the debt offering.

The placement agents received cash commissions of $251,000, representing 10% of the principal amount of the notes purchased, $62,750 in non-accountable expenses and due diligence fees (21/2% of the principal amount of the notes purchased), and five year warrants to purchase a maximum of 209,167 shares of the Company's common stock (which number will be adjusted and reduced when the initial conversion price of the notes is determined) exercisable at $2.69 per share, representing a price equal to 115% of the five day VWAP of the common stock of the Company up to the closing.

AMDL structured the debt financing so the conversion price will be determined at or about the same time as an anticipated 1st quarter 2009 "at market" public offering. Prior to this event, the Company expects to meet certain milestones that it believes will positively impact the conversion price. Specifically, AMDL intends to
'/>"/>

SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
2. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
3. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
4. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
5. Pathwork Diagnostics Closes $20M Financing
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. PAREXEL Closes the Acquisition of ClinPhone
8. Cytochroma Closes $45 Million Series C Financing
9. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
10. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
11. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... MA (PRWEB) August 21, 2014 ... company, has been recognized as one of the ... | 5000 magazine for the 2nd consecutive year. ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ...
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2
... HUBBARD, Ohio, April 8, 2008 NanoLogix, Inc.,(OTC ... 2007 financial data and a director appointment., ... were,reduced by 42% over 2006, while funding for ... information can be accessed at:, http://www.nanologixinc.com/financials.html , ...
... 8, 2008 Raven,biotechnologies, inc., a privately held ... antibody therapeutics (MAbs) for cancer,announced today that it ... under which Monogram will evaluate selected Raven,monoclonal antibodies ... cancer., "Raven,s extensive library of antibody candidates ...
... - The PerOs team is proud to announce,the ... the production,of bacterins as well as an autogenous ... (Oralject(TM))., "The approval of our manufacturing facility ... States marks a significant milestone for,our Company, and ...
Cached Biology Technology:NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director 2Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Human PDGF R beta MAb (Clone # PR7212)...
... Ambion's ActivePro In Vitro ... an E.coli lysate, synthesizes ... as well as proteins ... than competing kits. This ...
Biology Products: